- Home
- PTGX vs TERN Comparison
PTGX vs TERN Comparison
Compare PTGX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | TERN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.8B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PTGX | TERN |
|---|---|---|
| Price | $98.97 | $52.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $106.67 | $47.38 |
| AVG Volume (30 Days) | 811.3K | ★ 5.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.81 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $867.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.60 | $1.87 |
| 52 Week High | $105.69 | $53.19 |
Technical Indicators
Market Signals| Indicator | PTGX | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 76.77 |
| Support Level | $76.63 | $38.99 |
| Resistance Level | $100.00 | N/A |
| Average True Range (ATR) | 4.71 | 1.99 |
| MACD | 0.12 | 0.52 |
| Stochastic Oscillator | 53.74 | 97.70 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.